Obesity is no longer viewed only as a metabolic disorder; it is now a major cancer-promoting state. This review explains how excess adiposity drives cancer through intertwined biologic pathways including chronic inflammation, hormonal dysregulation, immune suppression, altered energy metabolism, DNA damage, and gut microbiome disruption.
Obesity is no longer viewed only as a metabolic disorder; it is now a major cancer-promoting state. This review explains how excess adiposity drives cancer through intertwined biologic pathways including chronic inflammation, hormonal dysregulation, immune suppression, altered energy metabolism, DNA damage, and gut microbiome disruption. For clinicians, the key message is practical: obesity is a modifiable cancer risk factor, and meaningful weight loss may reduce future cancer burden.
Main clinical message
Overweight and obesity are associated with higher rates of multiple cancers, especially endometrial, colorectal, liver, gallbladder, pancreas, kidney, postmenopausal breast, oesophagal adenocarcinoma, ovarian, thyroid, gastric, prostate, and multiple myeloma. The review estimates that obesity contributes to about 10% of new cancers annually in the US, and even more in selected tumour types such as endometrial and hepatobiliary malignancies.
Key biologic pathways
The review highlights 5 major mechanisms:
1. Adipose tissue dysfunction: enlarged adipocytes produce excess estrogens, leptin, inflammatory cytokines, and less adiponectin.
2. Chronic inflammation: IL-6, TNF-α, prostaglandin E2, and related mediators create a pro-tumor microenvironment.
3. Immune escape: obesity impairs cytotoxic T cells and NK cells while increasing immunosuppressive myeloid-derived suppressor cells.
4. Metabolic support for tumors: adipose tissue supplies free fatty acids and other fuel for cancer growth.
5. DNA damage and microbiome changes: oxidative stress and dysbiosis increase genomic instability and mucosal inflammation.
Important epidemiologic insights
Cancer risk is not determined by BMI alone. Patients with metabolically unhealthy obesity appear to have the highest cancer risk. The review also stresses that childhood and adolescent obesity trajectories may influence cancer risk later in life. Interestingly, obesity increases postmenopausal breast cancer risk, but may show a different association before menopause.
Weight loss and cancer prevention
The review suggests that modest weight loss may not be enough. A threshold of more than 10% body weight reduction may be needed to produce measurable reductions in obesity-related cancer risk. Observational data suggest benefit with:
Bariatric surgery, especially for endometrial cancer risk reduction
GLP-1 receptor agonists, with retrospective data suggesting lower incidence of some obesity-related cancers
Metformin and related metabolic therapies, though stronger prospective evidence is still needed
Practice implications
Clinicians should view obesity management as part of long-term cancer prevention, not only cardiovascular and metabolic risk reduction. Counselling should move beyond BMI to include metabolic health, waist circumference, adiposity pattern, and sustained weight-loss strategies. Multimodal care combining lifestyle measures, pharmacotherapy, and in selected patients, bariatric surgery may have future oncologic relevance.
Limitations of the review
Much of the evidence linking weight loss interventions to lower cancer incidence remains observational, not randomised. Several mechanistic pathways are strongly biologically plausible but not yet fully translated into cancer prevention trials.
Bottom line
Obesity promotes cancer through multiple biologic pathways, and meaningful sustained weight loss may reduce this risk. This review strengthens the concept that treating obesity is also part of cancer prevention.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.